Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Inclusion Criteria:

* Ability to understand and voluntarily sign an informed consent form
* Age \> 18 years at the time of signing the informed consent form
* Pathological confirmation of leukemia or myelodysplastic syndrome.
* AML according to WHO criteria; except for core-binding factor AMLs (t(8;21), inv(16) or t(16;16)) and APL
* ALL
* MDS
* Patients with AML include the following:
* Patients in 2nd or greater relapse
* Patients in first relapse with initial CR duration lasting \<6 months
* Patients in first relapse refractory to induction therapy
* Patients with primary refractory AML
* Patients with ALL include the following
* Patients with T-cell ALL refractory or in relapse following nelarabine
* Patients with other ALL that is refractory or in relapse.
* Patients with MDS include the following:
* The subset of RAEB-2 patients with \>10% blasts with at least 1 prior therapy that includes a hypomethylating agent.
* Previously untreated chemotherapy induced AML
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2
* Able to adhere to the study visit schedule and other protocol requirements
* Life expectancy of at least 12 weeks
* Laboratory values fulfilling the following:
* Serum creatinine \< 1.5 mg/dL
* Serum total bilirubin \< 1.5 mg/dL
* Serum alanine aminotransferase or aspartate aminotransferase \< 150 IU/liter Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
* Cardiac ejection fraction \> 50% by MUGA scan or echocardiography
* All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.

Exclusion Criteria:

* Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent form
* Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 24 hours before study entry
* Clinical evidence of active CNS leukemic involvement
* Pregnant or lactating women
* Clinically significant cardiac disease (New York Heart Association Class III or IV)
* Severe debilitating pulmonary disease
* Active and uncontrolled infection. Patients with an infection under active treatment with antibiotics and whose infection is controlled may be entered into the study
* Current evidence of invasive fungal infection (blood or tissue culture); HIV or hepatitis C infection
* Hypersensitivity to cytarabine, daunorubicin or liposomal products
* History of Wilson's disease or other copper-related disorder